Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis of the presented study is: Telmisartan induces an increase of eNOS activity in RBC resulting in an enhanced intravascular NO bioavailability, an ameliorated RBC deformability and a reduction of RBC and platelet aggregation. This could be a potential mechanism of the improvement of microcirculatory disorders, especially in patients with diabetes mellitus and arterial hypertension, treated with Telmisartan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients

NCT00560430

Hypertension Metabolic Syndrome Hypertriglyceridemia

COMPLETED PHASE3

Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension

NCT02176499

Hypertension

COMPLETED PHASE3

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients

NCT00863980

Acute Myocardial Infarction Angina Pectoris Myocardial Ischemia +2 more

TERMINATED NA

Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives

NCT00539487

Hypertension Obesity

COMPLETED

J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

NCT00659581

Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recently, it could be shown that the renin-angiotensin-system (RAS) influences different signal transduction pathways within the red blood cells (RBC). This includes the Na+/H+ exchange activity, the Ca2+-ATP-ase mediated Ca2+efflux, the erythropoietin- dependent production of RBC, the RBC deformability, RBC aggregation and the interaction of RBC and platelets. Recent studies and experiments, done by our group, focus on the oxidative and nitrosative metabolism of NO within the blood. The interactions of the RAS and endothelial NO are well known and described in detail. Based on a wide experience in this research field of NO metabolism, we characterized recently an active endothelial-type NO-synthase in RBC on the biochemical, functional and molecular level. Erythrocyte-derived NO formation serves important regulatory functions essential for adequate passage of blood through the vasculature. Here we aimed to treat patients with diabetes mellitus and arterial hypertension with Telmisartan as an angiotensin receptor antagonist. Efficacy parameters studied in this study should be: i) RBC deformability, RBC aggregation, ii) RBC dependent production of nitric oxide as well as detection of eNOS activity in RBC and iii) indices of microcirculatory perfusion. This project could broaden the view of effects of Telmisartan in the treatment of microcirculatory disorders in patients with diabetes mellitus and arterial hypertension, who exhibit a reduced NO bioavailability and RBC function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Hypertension Diabetes Mellitus Type 2 IRC or NIR

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

treatment with 80 mg Telmisartan per day for 30 days

Group Type EXPERIMENTAL

Telmisartan

Intervention Type DRUG

application of 80mg or 20mg Telmisartan per day for 30 days

B

treatment with 20mg Telmisartan per day for 30 days

Group Type ACTIVE_COMPARATOR

Telmisartan

Intervention Type DRUG

application of 80mg or 20mg Telmisartan per day for 30 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan

application of 80mg or 20mg Telmisartan per day for 30 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men older than 18 years
* Diabetes mellitus type 2 defined according to the criteria of the American Diabetes Association Arterial hypertension defined according to the criteria of the Joint National Committtees (JNC 7)
* Given informed consent

Exclusion Criteria

* Serve heart failure
* Serve aortic valve stenosis or hypertrophy obstructive cardiomyopathy
* Relevant cardiac arrhythmias
* Acute myocardial infarction within the last 4 weeks
* renal failure
* bilateral renal artery stenosis
* liver diseases
* primary hyperaldosteronism
* orthostatic hypotension (systolic blood pressure \<100mmHg)
* hypokalemia, hyponatremia, hypercalcemia, symptomatic hyperuricemia
* inflammatory disease
* malignant disease
* previous intolerance to AT1 receptor antagonists and/or sulfonamides
* current therapy with insulin sensitizer
* current therapy with digoxin
* known abuse of alcohol or drugs

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No